Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor
1997

Targeting Doxorubicin Resistance in Leukemia Cells

publication Evidence: moderate

Author Information

Author(s): S Suzuki, K Inoue, A Hongoh, Y Hashimoto, Y Yamazoe

Primary Institution: Tohoku University

Hypothesis

Can immunoliposomes targeting transferrin receptors overcome doxorubicin resistance in leukemia cells?

Conclusion

The study found that immunoliposomes can effectively increase doxorubicin sensitivity in doxorubicin-resistant leukemia cells.

Supporting Evidence

  • OKT9-CIL showed similar binding to both K562 and K562/ADM cells.
  • After treatment with OKT9-CIL, the difference in sensitivity to doxorubicin between K562 and K562/ADM was diminished.
  • DOX levels in K562/ADM after OKT9-CIL treatment were nearly equivalent to those in K562.

Takeaway

Researchers created special liposomes that can help a cancer drug work better in resistant leukemia cells.

Methodology

The study used doxorubicin-resistant K562/ADM leukemia cells and tested the effects of immunoliposomes on drug sensitivity and internalization.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication